209 related articles for article (PubMed ID: 24435119)
21. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
22. Sarcopenia as a prognostic factor among patients with stage III melanoma.
Sabel MS; Lee J; Cai S; Englesbe MJ; Holcombe S; Wang S
Ann Surg Oncol; 2011 Dec; 18(13):3579-85. PubMed ID: 21822551
[TBL] [Abstract][Full Text] [Related]
23. Value of DNA ploidy and S-phase fraction as prognostic factors in stage III cutaneous melanoma.
Martin G; Halwani F; Shibata H; Meterissian S
Can J Surg; 2000 Feb; 43(1):29-34. PubMed ID: 10714254
[TBL] [Abstract][Full Text] [Related]
24. Bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: a historical cohort study.
Espíndola MB; Corleta OC
World J Surg Oncol; 2008 Jun; 6():65. PubMed ID: 18570663
[TBL] [Abstract][Full Text] [Related]
25. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.
Balch CM; Gershenwald JE; Soong SJ; Thompson JF; Ding S; Byrd DR; Cascinelli N; Cochran AJ; Coit DG; Eggermont AM; Johnson T; Kirkwood JM; Leong SP; McMasters KM; Mihm MC; Morton DL; Ross MI; Sondak VK
J Clin Oncol; 2010 May; 28(14):2452-9. PubMed ID: 20368546
[TBL] [Abstract][Full Text] [Related]
26. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
27. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
28. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma.
Kelley MC; Jones RC; Gupta RK; Yee R; Stern S; Wanek L; Morton DL
Cancer; 1998 Oct; 83(7):1355-61. PubMed ID: 9762936
[TBL] [Abstract][Full Text] [Related]
29. Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy.
Wagner NB; Luttermann F; Gassenmaier M; Forschner A; Leiter U; Garbe C; Eigentler TK
Australas J Dermatol; 2020 Aug; 61(3):e310-e318. PubMed ID: 32050042
[TBL] [Abstract][Full Text] [Related]
30. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
[TBL] [Abstract][Full Text] [Related]
31. Contemporary surgical treatment of advanced-stage melanoma.
Essner R; Lee JH; Wanek LA; Itakura H; Morton DL
Arch Surg; 2004 Sep; 139(9):961-6; discussion 966-7. PubMed ID: 15381613
[TBL] [Abstract][Full Text] [Related]
32. Limitations of lymph node ratio, evidence-based benchmarks, and the importance of a thorough lymph node dissection in melanoma.
Grotz TE; Huebner M; Pockaj BA; Perkins S; Jakub JW
Ann Surg Oncol; 2013 Dec; 20(13):4370-7. PubMed ID: 24046102
[TBL] [Abstract][Full Text] [Related]
33. Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.
Rutkowski P; Nowecki ZI; van Akkooi AC; Kulik J; Wanda M; Siedlecki JA; Eggermont AM; Ruka W
Ann Surg Oncol; 2010 Dec; 17(12):3314-23. PubMed ID: 20607422
[TBL] [Abstract][Full Text] [Related]
34. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.
Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN
Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814
[TBL] [Abstract][Full Text] [Related]
35. A single-institution validation of the AJCC staging system for stage IV melanoma.
Neuman HB; Patel A; Ishill N; Hanlon C; Brady MS; Halpern AC; Houghton A; Coit DG
Ann Surg Oncol; 2008 Jul; 15(7):2034-41. PubMed ID: 18465172
[TBL] [Abstract][Full Text] [Related]
36. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).
Balch CM; Soong SJ; Murad TM; Smith JW; Maddox WA; Durant JR
J Clin Oncol; 1983 Feb; 1(2):126-34. PubMed ID: 6668496
[TBL] [Abstract][Full Text] [Related]
37. [Locally recurrent and metastatic malignant melanoma. Long-term results and prognostic factors after percutaneous radiotherapy].
Seegenschmiedt MH; Keilholz L; Pieritz A; Altendorf-Hofmann A; Urban A; Schell H; Hohenberger W; Sauer R
Strahlenther Onkol; 1999 Sep; 175(9):450-7. PubMed ID: 10518979
[TBL] [Abstract][Full Text] [Related]
38. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C;
Lancet Oncol; 2021 May; 22(5):643-654. PubMed ID: 33857412
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.
Balch CM; Soong SJ; Gershenwald JE; Thompson JF; Reintgen DS; Cascinelli N; Urist M; McMasters KM; Ross MI; Kirkwood JM; Atkins MB; Thompson JA; Coit DG; Byrd D; Desmond R; Zhang Y; Liu PY; Lyman GH; Morabito A
J Clin Oncol; 2001 Aug; 19(16):3622-34. PubMed ID: 11504744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
